Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 12/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13766252 | 1.00 | KAT2B (0.39) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL22303403 | 1.00 | KAT2B (0.39) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL18233551 | 0.94 | KAT2B (0.43) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL14472668 | 0.89 | KAT2B (0.34) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL20621874 | 0.89 | KAT2B (0.34) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL18236735 | 0.89 | KAT2B (0.34) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL22055532 | 0.83 | GAA (0.42) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL18183344 | 0.83 | KDM4E (0.40) | KAT2BKDM4EALDH1A1GAAL3MBTL1 | |
| SCHEMBL19720601 | 0.80 | KAT2B (0.40) | KAT2BBPTFKDM4EALDH1A1GAA | |
| SCHEMBL20079253 | 0.80 | KAT2B (0.40) | KAT2BBPTFKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028338-A2 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2021219091-A2 | QUINOXALINONE DERIVATIVE AS IRREVERSIBLE INHIBITOR OF KRAS G12C MUTANT PROTEIN | 北京泰德制药股份有限公司 (CN) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | KAT2B 4205/4885BPTF 2365/4885KDM4E 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.